Photocure Market Cap ($132.27 Million)
Market Cap & Net Worth: Photocure (PHO)
Photocure market cap. Photocure (OL:PHO) has a market capitalization of $132.27 Million (Nkr1.26 Billion) as of October 31, 2026. Listed on the OL stock exchange, this Norway-based company holds position #18020 globally and #152 in its home market, demonstrating a -7.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Photocure's stock price Nkr46.70 by its total outstanding shares 26916610 (26.92 Million).
Photocure Market Cap History (2015–2026)
Photocure market cap history from 2015 to 2026. Data shows growth from $118.68 Million to $132.27 Million (1.53% CAGR). Check latest Photocure stock price today for real-time trading data and today's change.
Photocure Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Photocure's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see PHO cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.38x
Photocure's market cap is 0.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $118.96 Million | $143.63 Million | $35.31 Million | 0.83x | 3.37x |
| 2017 | $77.32 Million | $150.91 Million | -$34.70 Million | 0.51x | N/A |
| 2018 | $135.96 Million | $181.51 Million | -$36.71 Million | 0.75x | N/A |
| 2019 | $253.50 Million | $281.56 Million | $31.83 Million | 0.90x | 7.96x |
| 2020 | $301.93 Million | $256.48 Million | -$22.40 Million | 1.18x | N/A |
| 2021 | $290.89 Million | $360.54 Million | -$30.90 Million | 0.81x | N/A |
| 2022 | $302.50 Million | $393.13 Million | -$71.86 Million | 0.77x | N/A |
| 2023 | $190.90 Million | $500.66 Million | $979.00K | 0.38x | 195.00x |
| 2024 | $175.61 Million | $525.39 Million | -$3.34 Million | 0.33x | N/A |
| 2025 | $202.23 Million | $532.58 Million | -$1.52 Million | 0.38x | N/A |
Competitor Companies of PHO by Market Capitalization
Companies near Photocure in the global market cap rankings as of October 31, 2026. See debt-free asset ratio of Photocure to understand what proportion of total assets are financed by equity.
Key companies related to Photocure by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Photocure (2015–2026)
Market capitalization of Photocure from 2015 to today. Between 2015 and today, Photocure's market cap moved from $118.68 Million to $ 132.27 Million, with a yearly change of 1.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr132.27 Million | -34.59% |
| 2025 | Nkr202.23 Million | +15.16% |
| 2024 | Nkr175.61 Million | -8.01% |
| 2023 | Nkr190.90 Million | -36.89% |
| 2022 | Nkr302.50 Million | +3.99% |
| 2021 | Nkr290.89 Million | -3.66% |
| 2020 | Nkr301.93 Million | +19.11% |
| 2019 | Nkr253.50 Million | +86.46% |
| 2018 | Nkr135.96 Million | +75.82% |
| 2017 | Nkr77.32 Million | -35.00% |
| 2016 | Nkr118.96 Million | +0.24% |
| 2015 | Nkr118.68 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Photocure was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $132.27 Million USD |
| MoneyControl | $132.27 Million USD |
| MarketWatch | $132.27 Million USD |
| marketcap.company | $132.27 Million USD |
| Reuters | $132.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination pro… Read more